We claim:

1. A compound of the formula (1)

wherein X is a pharmaceutically acceptable anion.

- 2. A compound of claim 1 wherein the central double bond is in the (E) configuration on (Z) configuration.
- 3. A compound of claim 2 which is the RS-RS diastereomer.
- 4. A compound of claim 2 which is the RS-RR diastereomer.
- 5. A mixture comprising the RS-RS, RS-RR and RR-RR diastereomers of a compound of the formula (1) as described in claim 2.
- 6. A pharmaceutical composition comprising a compound of formula (1)

 described in claim 1. In association with a pharmaceutically

 acceptable carrier.

- 7. A method of producing muscle relaxation in a mammal which comprises parenterally administering to a mammal an effective muscle relaxation amount of a compound of claim 1.
- 8. The method of claim 7 in which the compound is administered in a pharmaceutically acceptable carrier.
- 9. A compound of claim 1 where X is C1.
- 10. A mixture according to claim 5 wherein X is C1.
- 11. A composition according to claim 6 wherein X is Ci.
- 12. A method according to claim 7 wherein X is C1.
- 13. A compound of claim 1 which is the 2,2'[(£)-4-Octenedicylois(oxytrimethylene)]bis[18,38-1,2,3,4-tetranydro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoduinolinum] cation in association with a pharmaceutically acceptable anion.
- 14. A compound of claim 1 which is the

 (E)-(18,1'8,28,2'5)-2,2'-(4-Octenediovibis(oxytrimethylene)]bis[1,2,3,4-tetranydro-6,7-dimethoyoxy-2-methyl-1(3,4,5-trimethoxybenzyl)isoduinolinium] cation in association
 with a pharmaceutically acceptable arion.

15. A compound of claim 1 which is the 2,2'-[(E)-4-Octenedicy(bis)oxytrimethylene)]bis[(18,25)-1,2,3,4-tetranyoro-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)

isoquinolinium] cation in association with a pharmaceutically acceptable anion.

- 16. A method for producing muscle relaxation in a mammal which comprises parenterally administering to a mammal an effective muscle relaxant amount of one or more of the compounds of claims 13, 14, or 15.
- 17. A pharmaceutical composition comprising one or more of the compounds of claims 13, 14, or 15 and a pharmaceutically acceptable carrier therefor.
- 18. A compound of claim 13, 14, or 15, in which the anion is the chloride anion.